Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 71-81

  Martin, Darryl T ^a   Steinbach, Jill M ^b   Liu, Jingchun ^a   Shimizu, Shogo ^a   Kaimakliotis, Hristos Z ^a   Wheeler, Marcia A ^a   Hittelman, Adam B ^a   Mark Saltzman, W ^b   Weiss, Robert M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; NANOPARTICLE; POLYGLACTIN; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLADDER; BLADDER CANCER; BLADDER IRRIGATION; BLADDER PERMEABILITY; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; MOUSE; MUCOADHESION; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; URETER;

ANIMALS; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; NANOPARTICLES; RNA, SMALL INTERFERING; SURFACE PROPERTIES; URINARY BLADDER NEOPLASMS; UROTHELIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892569827     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0502     Document Type: Article

References (50)

1. Guha Sarkar S, Banerjee R. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J Control Release 2010;148:147-59.
2. Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm 2006;3:369-79.
3. Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M. New frontiers in intravesical therapies and drug delivery. Eur Urol 2006;50:1183-93; discussion 93.
4. Le Visage C, Rioux-Leclercq N, Haller M, Breton P, Malavaud B, Leong K. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004;171:1324-9.
5. Highley MS, van Oosterom AT, Maes RA, De Bruijn EA. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999;37:59-73.
6. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19.
7. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12:393-404.
8. Anthony T, Fong P, Goyal A, Saltzman WM, Moss RL, Breuer C. Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidism. J Pediatr Surg 2005;40:81-5.
9. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009;8:526-33.
10. Sirianni RW, Olausson P, Chiu AS, Taylor JR, Saltzman WM. The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats. Brain Res 2010;1321: 40-50.
11. McNeer NA, Chin JY, Schleifman EB, Fields RJ, Glazer PM, Saltzman WM. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther 2011;19:172-80.
12. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012;33:583-91.
13. Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, et al. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine 2013;9:1124-34.
14. Fahmy TM, Samstein RM, Harness CC, Saltzman WM. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005;26: 5727-36.
15. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 2000; 278:F867-74.
16. Dupont E, Prochiantz A, Joliot A. Penetratin story: an overview. Methods Mol Biol 2011;683:21-9.
17. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004;27:85-131.
18. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 2003;9:357-62.
19. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-61.
20. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 2011;6:765-74.
21. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
22. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3.
23. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm 2009;6:173-81.
24. Yoo JW, Doshi N, Mitragotri S. Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry. Macromol Rapid Commun 2010;31:142-8.
25. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004;377:159-69.
26. Quintino L, Baudet A, Larsson J, Lundberg C. FACS binding assay for analysing GDNF interactions. J Neurosci Methods 2013; 218:25-8.
27. Moutzouris DA, Falagas ME. Interstitial cystitis: an unsolved enigma. Clin J Am Soc Nephrol 2009;4:1844-57.
28. Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol 2010;12:e181-9.
29. Wein AJ. Practical uropharmacology. Urol Clin North Am 1991;18: 269-81.
30. Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G. Interstitial cystitis: bladder training with intravesical oxybutynin. J Urol 2000;163: 1818-22.
31. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011;32:6194-203.
32. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 2009;30:2790-8.
33. Kim WJ. Chitin, Chitosan, Oligosaccharides and Their Derivatives: Biological Activities and Applications. In:Kim S-K, editor. Electrostatic Properties of Chitosan: CRC Press; 2010. p. 117-25.
34. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 1998;17:33-58.
35. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999;16:1576-81.
36. Kos MK, Bogataj M, Veranic P, Mrhar A. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. Biol Pharm Bull 2006;29:1685-91.
37. Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv 2010;7:1191-207.
38. Eroglu M, Irmak S, Acar A, Denkbas EB. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. Int J Pharm 2002;235: 51-9.
39. Weecharangsan W, Opanasopit P, Ngawhirunpat T, Apirakaramwong A, Rojanarata T, Ruktanonchai U, et al. Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. Int J Pharm 2008;348:161-8.
40. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm 2012;9:1262-70.
41. Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21-32.
42. Smith J, Wood E, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm Res 2004;21:43-9.
43. Lladser A, Sanhueza C, Kiessling R, Quest AF. Is survivin the potential Achilles' heel of cancer? Adv Cancer Res 2011;111:1-37.
44. Yang D, Song X, Zhang J, Ye L, Wang S, Che X, et al. Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin 2010;42:137-44.
45. Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011;32:2662-72.
46. Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008;32:1049-56.
47. Techaarpornkul S, Wongkupasert S, Opanasopit P, Apirakaramwong A, Nunthanid J, Ruktanonchai U. Chitosan-mediated siRNA delivery in vitro: effect of polymer molecular weight, concentration and salt forms. AAPS Pharm Sci Tech 2010;11:64-72.
48. Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 2006;27:4815-24.
49. Koping-Hoggard M, Varum KM, Issa M, Danielsen S, Christensen BE, Stokke BT, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004;11:1441-52.
50. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-52.